Key result
Lp(a) shows no association with new-onset atrial fibrillation.
Why the study?
Studies addressing the relationship between atrial fibrillation and Lipoprotein(a) have demonstrated conflicting results.
Does elevated lipoprotein(a) increase the risk of new-onset atrial fibrillation?
Meta-Analysis
Does elevated lipoprotein(a) increase the risk of new-onset atrial fibrillation?
Effect estimate: HR 1.45 (95% CI 0.57-3.67)
p-value: p=.432
Elevated lipoprotein(a) levels, whether measured or genetically determined, are not associated with an increased risk of incident atrial fibrillation.
Lp(a) need not inform AF risk stratification; reinforces null causal link from both measured and genetic data.
Lipoprotein(a) (Lp[a]) is a particle consisting of a low-density lipoprotein (LDL)-like core connected to an apolipoprotein(a) chain, which is an established risk factor for cardiovascular disease. However, studies addressing the relationship between atrial fibrillation (AF) and Lp(a) demonstrated conflicted results. Thus, we sought to evaluate this relationship by conducting this systemic review and meta-analysis. We performed a comprehensive systematic search of health science databases, including PubMed, Embase, Cochrane Library, Web of Science, MEDLINE, and ScienceDirect, to identify all relevant literature from their inception to March 1, 2023. We identified nine related articles, which were eventually included in this study. Our study showed no association between Lp(a) with new-onset AF (HR = 1.45, 95% confidence interval [CI]: 0.57-3.67, p = .432). In addition, genetically elevated Lp(a) was not associated with the risk of atrial fibrillation (OR = 1.00, 95% CI: 1.00-1.00, p = .461). Different stratification of Lp(a) levels may have different outcomes. Also, higher Lp(a) levels may be inversely associated with the risk of developing AF compared to those with lower levels. Lp(a) levels were not associated with incident AF. Further research is needed to identify the mechanism underlying these results and better understand Lp(a) stratification for AF and the possible inverse association between Lp(a) and AF.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2023) conducted a meta-analysis in Atrial fibrillation. Lipoprotein(a) was evaluated on New-onset atrial fibrillation (HR 1.45, 95% CI 0.57-3.67, p=.432). Lipoprotein(a) levels were not significantly associated with the risk of new-onset atrial fibrillation (HR 1.45; 95% CI 0.57-3.67; p=0.432).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: